The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hepatocellular Carcinoma (HCC): A Global Perspective
Abstract
INTRODUCTION More than 600,000 people die of hepatocellular carcinoma (HCC) each year. Worldwide research on the disease needs to be intensified in both the medical and pharmaceutical fields, especially with a focus on providing help to areas where resources are limited. Treatment approaches depend on the stage of the disease at diagnosis and on access to complex treatment regimens. However, advanced disease is not curable, and management of advanced disease is expensive and only marginally effective in increasing quality-adjusted life years. The delivery of healthcare services for HCC can be improved by developing centers of excellence. Concentrating medical care in this way can lead to an increased level of expertise, so that resections are performed by surgeons who understand liver disease and the limitations of resection and other relevant procedures. Promising new agents are beyond the reach of those who would benefit most: in low-resource countries, sorafenib is out of the question for general use. For example, “snapshot” cost indications of monthly pharmacy prices for sorafenib are: $7300 in China, $5400 in the United States, $5000 in Brazil, €3562 in France, and $1400 in Korea (source: N Engl J Med. 2008;359:378–390; PMID 18650519). From a global perspective, therefore, the most urgent task is to prevent the occurrence of HCC. The only effective strategy is primary prevention of viral hepatitis, and in most countries this is already in place in the form of hepatitis B vaccination of newborns. Prevention of alcohol abuse and preventing the spread of hepatitis C virus (HCV) and metabolic syndrome are also relevant. Another important task is to prevent aflatoxin formation through proper care of crops and food storage. The next best approach is to increase awareness among the healthcare community to promote surveillance of patients who are at risk and achieve earlier diagnosis and resection or ablation of small lesions. Global Prevalence and Incidence HCC is the sixth most common malignancy worldwide. It is the fifth most common malignant disease in men and the eighth most common in women. It is the third most common cause of death from cancer, after lung and stomach cancer. HCC is the most common malignant disease in several regions of Africa and Asia. At least 300,000 of the 600,000 deaths worldwide occur in China alone, and the majority of the other 300,000 deaths occur in resource-challenged countries in sub-Saharan Africa. These devastating figures are most likely due to: Failure to recognize those at risk (with hepatitis B and/or C) High prevalence of risk factors in the population Lack of medical expertise and facilities for early diagnosis Lack of effective treatment after diagnosis Other important factors include poor compliance, with inadequate attendance or absent in surveillance programs and thus late presentation of patients with large tumors; low awareness of the benefits of HCC treatment and ways of preventing underlying liver disease; and a negative opinion among some physicians about screening. In Japan, the United States, Latin America, and Europe, hepatitis C is the major cause of HCC. The incidence of HCC is 2% to 8% per year in patients with chronic hepatitis C and established cirrhosis. In Japan, the mortality from HCC has more than tripled since the mid-1970s. HCV infection is responsible for 75% to 80% of cases and hepatitis B virus (HBV) for 10% to 15% of cases. HCV-related HCC has been linked to blood transfusions in the 1950s and 1960s, intravenous drug use, and the reuse of syringes and needles. In many (but not all) countries, the spread of HCV is declining, but due to migration the disease burden has not changed. In Asia, Africa, and in some eastern European countries, chronic hepatitis B is the prime cause of HCC, far outweighing the impact of chronic hepatitis C (Fig. 1). There are 300 million people infected with HBV, 120 million of whom are Chinese. In China and Africa, hepatitis B is the major cause of HCC; approximately 75% of the HCC patients have hepatitis B.FIGURE 1.: The worldwide geographic distribution of chronic hepatitis B virus infection (source: Centers for Disease Control, 2006).HCC Risk Factors HCC is associated with liver disease independently of the specific cause of the disease: Infectious: chronic hepatitis B or C. Nutritional and toxic: alcohol, obesity (nonalcoholic fatty liver disease), aflatoxin (cofactor with HBV), tobacco. Genetic: tyrosinosis, hemochromatosis (iron overload). However, iron overload as a cause per se and as a result of dietary intake (due to cooking in iron pots) is a subject of controversy. α1-antitrypsin deficiency. Immunologic: autoimmune chronic active hepatitis, primary biliary cirrhosis. The major risk factors for HCC are: Chronic HBV or HCV infection. Alcoholic cirrhosis. Nonalcoholic steatohepatitis. Diabetes (metabolic syndrome is the likely risk process). Cirrhosis by itself, of whatever cause. In Europe, North America,
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citation
Cited by
Peng, Y.-F., Shi, Y.-H., Ding, Z.-B., Ke, A.-W., Gu, C.-Y., Hui, B., Zhou, J., Qiu, S.-J., Dai, Z., & Fan, J. (2013) · Autophagy · doi:10.4161/auto.26398 · Cited by 295
Xu, Q., Tu, J., Dou, C., Zhang, J., Yang, L., Liu, X., Lei, K., Liu, Z., Wang, Y., Li, L., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0748-y · Cited by 283
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 269
(2012) · doi:10.1158/0008-5472.can-12-0388 · Cited by 242
Gai, X., Tu, K., Li, C., Lu, Z., Roberts, L. R., & Zheng, X. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.76 · Cited by 54
Retracted
Metadata
- Authors
- Ferenci, P., Fried, M., Labrecque, D., Bruix, J., Sherman, M., Omata, M., Heathcote, J., Piratsivuth, T., Kew, M., Otegbayo, J. A., Zheng, S. S., Sarin, S., Hamid, S. S., Modawi, S. B., Fleig, W., Fedail, S., Thomson, A., Khan, A., Malfertheiner, P., Lau, G., Carillo, F. J., Krabshuis, J., & Le Mair, A.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2010-04
- Volume
- 44
- Issue
- 4
- Pages
- 239-245
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W1974682739
- Cited by
- 322
- References
- 1
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocellular Carcinoma (HCC): A Global Perspective. https://app.cochat.ai/papers/10.1097/mcg.0b013e3181d46ef2
- The paper
- Ferenci, P., Fried, M., Labrecque, D., Bruix, J., Sherman, M., Omata, M., Heathcote, J., Piratsivuth, T., Kew, M., Otegbayo, J. A., Zheng, S. S., Sarin, S., Hamid, S. S., Modawi, S. B., Fleig, W., Fedail, S., Thomson, A., Khan, A., Malfertheiner, P., . . . Le Mair, A. (2010). Hepatocellular Carcinoma (HCC): A Global Perspective. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e3181d46ef2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.